The highly anticipated financial results for the third quarter of Harmony Biosciences Holdings (NASDAQ: HRMY) are scheduled to be disclosed on Tuesday 29th October 2024. This important update will be made available before market open, providing investors and market participants with key information regarding the company's financial status.
In accordance with the predictions of financial analysts on Wall Street, the concern is on track to report an expected per share of $0.66 profit for the quarter. Furthermore, the firm is projected to disclose a total revenue of $184.06 million for this quarter.
The company's earnings report for the corresponding quarter of the previous year showcased a per-share income of $0.97. This notable figure was achieved due to the company's impressive total revenue of $160.27 million recorded during that specific period.
Wall Street analysts have revealed their projections for the company's yearly performance, with a total revenue of $710.13 million. Furthermore, they expect the business to achieve profit of $2.23 per share during the fiscal year.
| Period | EPS Actual |
EPS Growth* |
Revenue Actual |
Revenue Growth* |
|---|---|---|---|---|
| Historical Earnings Insight | ||||
| Q2 2024 | $1.05 | +38.2% | 172.81 M | +28.8% |
| Q1 2024 | $0.88 | +33.3% | 154.62 M | +29.8% |
| Q4 2023 | $0.73 | -27.7% | 168.41 M | +31.3% |
| Q3 2023 | $0.97 | +2.1% | 160.27 M | +36.7% |
| Q2 2023 | $0.76 | +33.3% | 134.22 M | +25.4% |
| *Growth on year-over-year basis | ||||
HRMY has scheduled a conference call on 29th October 2024 at 08:30 AM eastern time to discuss the third quarter financial results and other related information.
Harmony Biosciences Holdings (HRMY) closed Friday's regular trading session at $34.50, showing a 1.32 percent rise. During the day, HRMY shares traded between $33.91 and $34.90, with a day volume of 450.80 thousand shares.
